Successful anti-PD-1 antibody treatment in a metastatic melanoma patient with known severe autoimmune disease

Journal of Immunotherapy

Volumn 39, Issue 4, 2016, Pages 188-190

  Maul, Lara V ^a   Weichenthal, Michael ^a   Kähler, Katharina C ^a   Hauschild, Axel ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Anti PD 1 antibody; Autoimmune disease; Melanoma

Indexed keywords

AZATHIOPRINE; CALGRANULIN; CARBOPLATIN; DACARBAZINE; IPILIMUMAB; LACTATE DEHYDROGENASE; PACLITAXEL; PEMBROLIZUMAB; PREDNISOLONE; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN S100B; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ABDOMINAL TUMOR; AGED; ARTICLE; AUTOIMMUNE DISEASE; CANCER STAGING; CASE REPORT; CHURG STRAUSS SYNDROME; COLITIS; COUGHING; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRY SKIN; EOSINOPHIL COUNT; FATIGUE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HYPEREOSINOPHILIA; IMMUNOSUPPRESSIVE TREATMENT; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; METASTATIC MELANOMA; MIXED TUMOR; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; PULMONARY VASCULITIS; SKIN METASTASIS; SOFT TISSUE METASTASIS; TUMOR VOLUME; CHURG-STRAUSS SYNDROME; COMPLICATION; IMMUNOLOGY; MELANOMA; METASTASIS; PATHOLOGY; REMISSION; SKIN NEOPLASMS;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CHURG-STRAUSS SYNDROME; HUMANS; MALE; MELANOMA; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGRAMMED CELL DEATH 1 RECEPTOR; REMISSION INDUCTION; SKIN NEOPLASMS;

EID: 84961942697     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000118     Document Type: Article

References (9)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2013;363:711-723.
2. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-2526.
3. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372: 2521-2532.
4. Ribas A, Hodi FS, Kefford R, et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL) (Abstract LBA9000). J Clin Oncol. 2014;32:5.
5. Kong YC, Flynn JC. Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors Anti-CTLA-4 and Anti-PD-1. Front Immunol. 2014;5:206.
6. Koukoulaki M, Smith KG, Jayne DR. Rituximab in Churg-Strauss syndrome. Ann Rheum Dis. 2006;65:557-559.
7. Wang HB, Shi FD, Li H, et al. Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol. 2001;166:6430-6436.
8. Johnson DB, Khushalani NI, Puzanov I, et al. Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. JAMA Oncol. 2016;2:234-240.
9. Weber JS, Kudchadkar RR, Yu B, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or naive melanoma. J Clin Oncol. 2013;31:4311-4318.